PMID- 38098038
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20231217
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Print)
IS  - 1465-9921 (Linking)
VI  - 24
IP  - 1
DP  - 2023 Dec 14
TI  - Acarbose reduces Pseudomonas aeruginosa respiratory tract infection in type 2 
      diabetic mice.
PG  - 312
LID - 10.1186/s12931-023-02619-8 [doi]
LID - 312
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is widely prevalent worldwide, and 
      respiratory tract infections (RTIs) have become the primary cause of death for 
      T2DM patients who develop concurrent infections. Among these, Pseudomonas 
      aeruginosa infection has been found to exhibit a high mortality rate and poor 
      prognosis and is frequently observed in bacterial infections that are concurrent 
      with COVID-19. Studies have suggested that acarbose can be used to treat T2DM and 
      reduce inflammation. Our objective was to explore the effect of acarbose on P. 
      aeruginosa RTI in T2DM individuals and elucidate its underlying mechanism. 
      METHODS: High-fat diet (HFD) induction and P. aeruginosa inhalation were used to 
      establish a RTI model in T2DM mice. The effect and mechanism of acarbose 
      administered by gavage on P. aeruginosa RTI were investigated in T2DM and 
      nondiabetic mice using survival curves, pathological examination, and 
      transcriptomics. RESULTS: We found that P. aeruginosa RTI was more severe in T2DM 
      mice than in nondiabetic individuals, which could be attributed to the activation 
      of the NF-kappaB and TREM-1 signaling pathways. When acarbose alleviated P. 
      aeruginosa RTI in T2DM mice, both HIF-1alpha and NF-kappaB signaling pathways were 
      inhibited. Furthermore, inhibition of the calcium ion signaling pathway and NF-kappaB 
      signaling pathway contributed to the attenuation of P. aeruginosa RTI by acarbose 
      in nondiabetic mice. CONCLUSIONS: This study confirmed the attenuating effect of 
      acarbose on P. aeruginosa RTIs in T2DM and nondiabetic mice and investigated its 
      mechanism, providing novel support for its clinical application in related 
      diseases.
CI  - (c) 2023. The Author(s).
FAU - Liu, Lin
AU  - Liu L
AD  - Department of Otolaryngology, The Seventh Affiliated Hospital, Sun Yat-Sen 
      University, Shenzhen, People's Republic of China.
AD  - Department of Pharmacology, School of Medicine, Southern University of Science 
      and Technology, Shenzhen, People's Republic of China.
AD  - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 
      Shenzhen, China.
FAU - Fan, Haiyang
AU  - Fan H
AD  - Department of Otolaryngology, The Seventh Affiliated Hospital, Sun Yat-Sen 
      University, Shenzhen, People's Republic of China.
AD  - Department of Pharmacology, School of Medicine, Southern University of Science 
      and Technology, Shenzhen, People's Republic of China.
AD  - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 
      Shenzhen, China.
FAU - Li, Liang
AU  - Li L
AD  - Department of Pharmacology, School of Medicine, Southern University of Science 
      and Technology, Shenzhen, People's Republic of China. lil@sustech.edu.cn.
AD  - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 
      Shenzhen, China. lil@sustech.edu.cn.
FAU - Fan, Yunping
AU  - Fan Y
AD  - Department of Otolaryngology, The Seventh Affiliated Hospital, Sun Yat-Sen 
      University, Shenzhen, People's Republic of China. zhfanyp@163.com.
LA  - eng
GR  - JCYJ20190809143601759/Shenzhen Fundamental Research Program/
GR  - JCYJ20190809143601759/Shenzhen Fundamental Research Program/
GR  - SZSM202111005/Sanming Project of Medicine in Shenzhen/
PT  - Journal Article
DEP - 20231214
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
RN  - T58MSI464G (Acarbose)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Humans
MH  - Mice
MH  - Animals
MH  - Acarbose/pharmacology/therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Pseudomonas aeruginosa/metabolism
MH  - NF-kappa B/metabolism
MH  - *Diabetes Mellitus, Experimental/drug therapy
MH  - *Pseudomonas Infections/drug therapy
MH  - *Respiratory Tract Infections/drug therapy
PMC - PMC10722695
OTO - NOTNLM
OT  - Acarbose
OT  - NF-kappaB signaling pathway
OT  - P. aeruginosa
OT  - Respiratory tract infection
OT  - Type 2 diabetes mellitus
COIS- No conflicts of interest, financial or otherwise.
EDAT- 2023/12/15 06:42
MHDA- 2023/12/17 17:43
PMCR- 2023/12/14
CRDT- 2023/12/15 00:20
PHST- 2023/09/10 00:00 [received]
PHST- 2023/11/28 00:00 [accepted]
PHST- 2023/12/17 17:43 [medline]
PHST- 2023/12/15 06:42 [pubmed]
PHST- 2023/12/15 00:20 [entrez]
PHST- 2023/12/14 00:00 [pmc-release]
AID - 10.1186/s12931-023-02619-8 [pii]
AID - 2619 [pii]
AID - 10.1186/s12931-023-02619-8 [doi]
PST - epublish
SO  - Respir Res. 2023 Dec 14;24(1):312. doi: 10.1186/s12931-023-02619-8.